Abstract: The management of prostate cancer patients is rapidly changing. The extended survival seen in randomized phase III trials with new molecules has significantly enriched the therapeutic armamentarium, and ongoing clinical trials are assessing whether the integration of these active drugs within established therapeutic regimens results in a further benefit for patients. This complex scenario is raising the need for the identification and validation of biomarkers able to drive the decision-making process during the course of the disease. Compelling evidence has documented the role of microRNAs in cancer biology, and their multifaceted biological activity makes them an attractive candidate as diagnostic, prognostic, and predictive biomarkers. This review summarizes the current knowledge about microRNA deregulation in prostate cancer, how these molecules have been investigated in the clinical setting, and strategies investigators should consider for sharpening their potential.
P
rostate cancer is one of the leading causes of cancerrelated death. Although major breakthroughs in translational oncology have been made in recent years, many issues have to be addressed to better manage these patients. First, the extent to which the mortality declined in the ''prostate-specific antigen (PSA) era'' is still debated since PSA-based screening programs have led to nonnegligible overdiagnosis and overtreatment. 1 Second, risk assessment of newly diagnosed prostate cancer patients continues to rely on clinical-pathological features, combined in either risk stratification models or nomograms, whose predictive accuracy are far from ideal. 2 Furthermore, imaging techniques that are exploited for tumor staging are unable to detect micrometastatic diseases. When considering the advanced setting, a wave of clinical trials culminated in the approval of the new chemotherapeutic agent cabazitaxel, 3 the active cellular immunotherapy sipuleucel-T, 4 and the cytochrome P17 inhibitor abiraterone acetate. 5 Even though these compounds extended overall survival in randomized phase III trials, the increasing availability of active drugs has presented an urgent need for establishing optimal association/sequential strategies and for identifying predictive biomarkers of response. Therefore, novel and versatile molecular parameters able to drive the decision-making process throughout the course of the disease are urgently needed.
Growing evidence indicates that a gene family, called microRNAs (miRs), controls almost all basic cellular functions, spanning from cell cycle and apoptosis to ''stemness'' maintenance and resistance to chemotherapy. 6 MicroRNAs are endogenous, evolutionarily conserved, noncoding RNAs that control protein expression at the posttranscriptional level mainly by inhibiting the translation of target mRNAs. 7 The mature forms, È22 nucleotide (nt) long single-stranded RNAs, originate from a multistep processing of longer precursors. The primary transcripts (pri-miRs), which can be thousands of nucleotides long, are target for an endonucleolytic cleavage operated by the nuclear enzyme Drosha whose activity produces È70-nt hairpin structures named pre-miRs. 8 These molecules are further processed by the ribonuclease Dicer into double-stranded RNAs containing the mature miR and its bulged antisense sequence (miR*). 9 Finally, the mature form is incorporated into RISC (RNA-induced silencing complex), where miRs silence target mRNAs by recognizing partially complementary sequences residing in the 3 ¶ untranslated region (UTR). 10 The miR-based gene expression control is an intricate network of interactions; each miR can bind several mRNAs, whereas each target can be modulated by multiple miRs. 11 It is well documented that deregulated miR levels contribute to cancer. Up-regulated miRs inhibiting tumor suppressor genes have been termed oncomirs, whereas down-regulated miRs that promote cancer progression are known as tumor-suppressor miRs. Recently, miRs have moved from the laboratory setting to be investigated in clinical trials. 12Y14 This review discusses miRs contribution to the pathobiology of prostate cancer and their utility in the clinical setting.
MIR PROFILING IN PROSTATE CANCER
Because many miRs are differentially expressed between normal and malignant tissues, miR expression profiles are considered to be potential tools for the diagnosis and prognosis of cancer. Nevertheless, a close comparison of different miR expression profiles highlights that a conclusive signature of miRs deregulated in prostate cancer is still missing. Differences in study design, sensitivity and specificity of the used platforms, underestimated patient treatments, methods of sample collection, and presence of contaminating nonepithelial cells may be some possible explanations for such inconsistent results. 15 By comparing total RNA extracted from 56 prostate tumors and 7 tissues from noncancerous individuals, the study of Volinia et al 16 verified a general up-regulation of miRs in cancer: specifically, 39 miRs were up-regulated and 6 were down-regulated in prostate cancer. These results were in partial agreement with a more focused study conducted in a similar experimental setting by Ambs et al, 17 who analyzed total RNA extracted from 60 microdissected prostate cancers and 16 surrounding nontumor tissues. Different results were shown by other groups, having observed instead a down-regulation of miRs in prostate cancer. Porkka et al 18 analyzed small RNA obtained from 6 prostate cancer cell lines, 9 prostate cancer xenografts, and 13 clinical prostate tissues, specifically 4 benign prostatic hyperplasia (BPH), 5 untreated prostate carcinomas, and 4 hormone-refractory prostate carcinomas. The comparison of the clinical samples led to identifying 51 differentially expressed miRs, specifically 37 down-regulated and 14 up-regulated in carcinoma samples versus the BPH group. The miR expression pattern obtained by Porkka et al 18 was different, if not reversal, from the profiles of Volinia et al 16 and Ambs et al, 17 while discretely overlapping the one generated by Ozen et al. 19 In the latter study, the authors compared 16 prostate cancer tissues and 10 normal prostate tissues and observed a widespread down-regulation of miRs in human prostate cancer. In particular, 76 miRs were down-regulated, with a tendency toward a more pronounced down-regulation in cases with early PSA recurrence. Tong et al 20 analyzed 40 formalinfixed paraffin-embedded prostatectomy specimens with T2a/b stage tumor, including 20 with biochemical relapse within 2 years from prostatectomy and 20 without relapse for 10 years. For each specimen, malignant involved areas were microdissected and compared with uninvolved areas. 20 The main findings of this study were the down-regulation of some miRs in agreement with the analysis of Porkka et al 18 and the tendency of early tumor relapse to display a distinguished miR signature. Schaefer et al 21 performed a microarray analysis of miRs in 24 matched pairs of histologically confirmed tumors and normal adjacent tissues and validated their results in 76 additional tissue pairs. They identified a set of 10 deregulated miRs, among which miR-205 down-regulation and miR-183 up-regulation had the highest capability to discriminate between normal and tumor-affected tissue, whereas miR-96 overexpression was found to be a negative prognostic indicator, being inversely correlated with the recurrence-free interval. 21 Subsequently, Szczyrba et al 22 compared the miR profiles of normal versus neoplastic prostate tissues by deep sequencing of the small RNA fraction, with miR-375 resulting the most up-regulated and miR-143 and -145 the most down-regulated. More recently, Martens-Uzunova et al 23 evaluated the noncoding RNA transcriptome of organ-confined prostate cancer and metastatic locoregional lymph nodes by deep sequencing. They also investigated by microarray whether miR expression profiles can distinguish normal tissues from malignant ones and further discriminate different prostate cancer subtypes. Eighty miRs were identified as having significantly changed between normal and malignant tissues. Among these, 22 significantly contributed to the separation of tumors associated with clinical progression and development of metastases, including miR-143, -145, -221, -222, and -205 down-regulation and miR-25, -96, -182, and -183 up-regulation. 23 In an attempt to identify miRs involved in the development of metastasis, Watahiki et al 24 have recently compared small RNA isolated from metastatic and nonmetastatic prostate cancer tissue xenografts by sequencing. Some of the differentially expressed miRs had previously been associated with prostate cancer, such as miR-16, -29, -145, and -205. Although a synopsis of all these studies underlines that much controversy is still segregating results, a much clearer picture is starting to emerge from the reported deregulation of some miRs in multiple studies. Table 1 summarizes the miRs whose up-or down-regulation has been consistently described in at least 3 different studies, including expression profile analyses and focused studies on specific miRs.
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MIRS AND CELL CYCLE CONTROL AND APOPTOSIS
Accumulating evidence demonstrates that an alteration of miR levels strongly impacts several aspects of cell biology, including the regulation of mechanisms governing cell cycle and apoptosis. Reduced levels of tumor-suppressor miRs can result in the up-regulation of cell cycle promoters or apoptosis inhibitors, whereas increased levels of oncogenic miRs can lead to the down-regulation of cell cycle inhibitors or apoptotic mediators. Consistently, the protumorigenic effects induced by miR-15/16 down-regulation in prostate cells have been related to their capacity to posttranscriptionally repress BCL2, CCND1, and WNT3A, thus interfering with multiple oncogenic activities. 34 Interestingly, an atelocollagen-mediated delivery of synthetic In the study of Watahiki et al, 24 up-or down-regulation of miRNAs in metastatic versus nonmetastatic prostate cancer. MicroRNAs whose deregulation has been consistently described in at least 3 different studies were included in the table.
miR-16 significantly inhibited the growth of prostate tumors in the bone, 35 and a gene copy-number analysis of the miR-15a/16 gene cluster identified a homozygous deletion in 2 prostate cancer xenografts and a heterozygous deletion in most of the other samples studied. 47 The cell cycle promoter CCND1 is also targeted by miR-449a, 48 whereas CCND2 and the transcription factor E2F2 can be increased by reduced levels of the tumor suppressor let-7a, 49 already shown to repress the oncogenes RAS, MYC, and HMGA2.
50Y52 Several studies have implicated the miR-34 family of miRs in the p53 tumor suppressor network. 53, 54 The expression of miR-34 is induced by DNA damage and oncogenic stress in a p53-dependent manner. MicroRNA-34 activation can recapitulate elements of p53 activity, inducing cell cycle arrest and apoptosis by the down-modulation of proteins such as CDK4, CDK6, cyclin D1, cyclin E2, E2F3, and BCL2. 55Y57 Conversely, loss of miR-34 can impair p53-mediated cell death. 58, 59 The member of the family miR-34c was found to inversely correlate with prostate cancer patients' risk, and in prostate cell lines, miR-34c ectopic expression decreased cell growth and increased apoptosis by negatively regulating the oncogenes E2F3 and BCL2. 60 Similarly, miR-330 has been reported to induce apoptosis of prostate cancer cells through E2F1-mediated suppression of AKT phosphorylation, 61 whereas down-regulation of miR-205 and miR-31 contributes to apoptosis resistance by targeting BCL2L and E2F6, respectively.
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The well-established tumor suppressive cluster miR-143/145 has also been shown to participate in prostate tumorigenesis. In particular, miR-143 reduction can enhance activation of the mitogen-activated protein kinase cascade via up-regulation of ERK5, 29 and miR-145 can hinder cell death via up-regulation of BNIP3, 62 a mitochondrial protein functioning as a transcriptional corepressor of the apoptosis-inducing factor gene AIF. 63 The contribution of miR-146 down-regulation to prostate cancer progression has been previously described in its capacity to repress ROCK1 expression, 64 a downstream effector of hyaluronan-mediated signaling on CD168 receptor. Hyaluronan is synthesized by fibroblasts and is crucial for the development and progression of hormone-refractory prostate cancer. 65 More recently, miR-146 has been reported to target EGFR, thus contributing to the activation of its oncogenic ERK-mediated pathway. 66 Similarly, miR-148 down-regulation may stimulate signaling upon EGFR activation via up-regulation of mitogenand stress-activated kinase 1 (MSK1), a serine and threonine kinase, which is a downstream target of ERK and p38 mitogenactivated protein kinase. 67 The miR-99 family members miR99a, -99b, and -100 were also described as down-regulated in prostate cancer as compared with normal prostate; growth inhibition upon their transfection has been correlated with inhibition of chromatin-remodeling factors SMARCA5 and SMARD1 and of the growth regulatory kinase mTOR. 27 MicroRNA-22 and the miR-106bÈ25 cluster are instead overexpressed in prostate cancer, and they potentiate cellular transformation by negatively regulating the tumor suppressor PTEN. 45 The 2 closely related miR-221 and miR-222 are described as being among the most frequently overexpressed miRs in cancer. Increased levels of these 2 miRs have been reported to sustain the development of castration-resistant prostate cancer. 43 Ectopic introduction of miR-221/222 in low expressers LNCaP cells strongly increased their growth potential by inducing a G1-S shift, while antiYmiR-221/ 222 treatment of high expressers PC3 cells reduced tumor growth. 42 An inverse correlation between the expression of miR-221/222 and the cell cycle inhibitor, p27 Kip1 , 41, 42 has been described. Notwithstanding, the role of these miRs is still controversial, as low levels of miR-221/222 have been found in several microarray studies (Table 1 ). In conclusion, many miRs have been connected with cell cycle kinetics and the apoptotic machinery. Because the balance between proapoptotic and antiapoptotic molecules has been widely studied for predicting the benefit from many chemotherapeutic agents, cell cycleY and/or apoptosis-linked miRs can be also explored for this purpose. To a similar extent, these miRs are worth being investigated to predict the activity of apoptosis-acting biomolecules that are undergoing clinical development.
MIRS AND PROSTATE CANCER METASTASIS
Prostate cancer cells are characterized by a tendency toward skeletal metastatization. Bone metastases are detectable in about 70% of advanced prostate cancer patients and are responsible for severe skeletal morbidity and poor clinical outcomes. 68 A passive metastatization model (''mechanical trapping'' theory) was originally proposed to explain the metastatic pattern of solid tumors. This model, however, fails to explain the organ-specific dissemination of many cancers. The site-specific spreading of tumors was proposed in 1889 by Paget's ''seed and soil'' theory, which postulated that tumor cells (seeds) colonize distant organs (soil) having a favorable microenvironment. Molecular events underlying this behavior have been, at least in part, clarified. The metastatic cascade is defined as a nonrandom and multistep process requiring a series of coordinate events, spanning from extracellular matrix invasion and neoangiogenesis at the primary tumor site to adaptation to survive in a foreign soil. 69 The epithelial-mesenchymal transition (EMT), a drastic cytoskeletal rearrangement pictured by the E cadherin to N cadherin switch, is considered a further key step toward cancer metastasis. 70 Once within the skeleton, the interaction between tumor cells and the bone microenvironment fuels a vicious circle between neoplastic proliferation and osteoclast-and osteoblast-mediated bone remodeling, which culminates in tumor progression and bone destruction. 71 A comparison of differentially expressed miRs in primary tumors and bone metastasis identified miR-143 and -145 as significantly decreased in bone lesions. 28 The tumor-suppressive role of these miRs has been confirmed in in vitro experiments documenting the repressed migration and invasion following their forced overexpression in commercial cell lines. Consistent with in vitro results, miR-143 and -145 overexpressing cells possessed less skeletal invasive ability compared with control upon intratibial injection. Increased miR-143 or miR-145 levels have also been connected to EMT reversion, as indicated by both an increase in E cadherin levels and a morphologic switch from a mesenchymal-like cellular shape to an epithelial-like shape. MicroRNA-205 is highly represented in normal prostate tissue, whereas reduced miR-205 expression has been found in untreated prostatic adenocarcinomas. 37 When miR-205 was restored in metastatic DU145 prostate cancer cells, they underwent a transition from a motile fibroblastic-like toward an epitheliallike phenotype, thus resembling a reverse EMT. The miR-205Y mediated reversion of the EMT was correlated with the direct targeting of protein kinase CD and the EMT-associated transcription factor ZEB2. However, the phenotype reminiscent of that observed in miR-205Yexpressing cells has been observed when protein kinase CD, rather than ZEB2, was interfered. Gene expression profiling of miR-205Ytransfected cells revealed a general up-regulation of cell junctionYassociated genes coupled with a down-regulation of several tumor-enhancing factors including the osteoclast-activating cytokine interleukin 6. Even though bone metastases in prostate cancer are typically osteoblastic, an enhanced osteoclastic activity is also required as highlighted by both the increase in bone resorption markers and the activity of antiresorptive drugs in bone metastatic prostate cancer patients. 72, 73 Therefore, miR-205 loss may represent a crucial event for the establishment of bone metastases. Micro-RNA-146 also belongs to commonly down-modulated miRs in prostate cancer, and its metastasis-repressive role has been linked with the targeting of ROCK1. 64, 65 The ROCK-mediated signal transduction pathway exerts multiple prometastatic activities: enhanced migratory ability, 74 activation of the oncogenic Akt/ mTOR/eIF4E signaling, and production of macrophage colony stimulating factor, a cytokine promoting preosteoclast proliferation. 75 Although reported in a completely different system, miR-146 also inhibits the translation of the CXCL12 receptor CXCR4. 76 In a pathological context, CXCL12 chemoattracts cancer cells equipped with the cognate receptor CXCR4, given the gradient existing between the bone microenvironment and the primary tumor site. 77 In addition, the CXCL12/CXCR4 axis contributes to the formation of the ''premetastatic niche'' 78 and recruits neoangiogenesis-contributing endothelial progenitor cells at the primary tumor site (''primary tumor niche''). 79 The multifaceted antimetastatic property of miR-146a is completed by its ability to repress the epidermal growth factor receptor and to constrain matrix invasion via the inhibition of the matrix metalloproteinase 2. 66 The list of miRs mechanistically associated with molecular mechanisms of bone metastases is completed by miR-203, whose expression is attenuated in the bone metastatic disease. 80 This miR represses a cohort of genes involved in multiple steps of the metastatic cascade. Established miR-203 targets are the EMT factor ZEB2 and the bone-specific effector RUNX2, a transcriptional regulator involved in bone homing and a regulator of osteoblast proliferation. Finally, miR-203 inhibits the polycomb repressor BMI1, a mediator involved in ''stemness'' maintenance, 81 thus allowing to postulate that this miR could be implicated in prostate cancer stem cell fate. Even though prostate cancer cells endowed with stem-like features have been isolated, the real target of the oncogenic process within the prostate is still debated, and whether a basal or a luminal progenitor is the source of the whole tumor population remains unclear. 82, 83 Cancer stem cells, a cellular subset connected with tumor formation, metastasis, and chemotherapy resistance, 84 have been identified in many tumors by using the adhesion molecule CD44. 85 It has been proved that miR-34a, which directly targets CD44, is underexpressed in CD44+ prostate cancer cells obtained from xenograft and primary tumors, whereas its forced expression in the cancer stem cell compartment abolished clonogenic expansion, tumor recapitulation in mice, and metastasis formation. 86 Genomic loss accounts for miR-101 deregulation. 87 MicroRNA-101 ectopic expression in metastatic prostate cancer cells attenuated their proliferation in vitro and in vivo and impaired their invasive potential. The zeste homolog 2 (EZH2), whose preponderant activity is gene silencing via histone H3 trimethylation, 88 is a target of miR-101, and it is known to promote anchorage-independent growth and invasion. Furthermore, miR-101 is regulated by key oncogenic pathways such as the hypoxia sensors hypoxia-inducible factor 1>/1A and the androgen receptor (AR). 89 Microenvironmental influences are also implicated in the metastatic process. Cancer-associated fibroblasts are known to promote malignant transformation, tumor growth, and progression. 90 MicroRNA-15 and miR-16.2 miRs for which genomic loss underpins their deregulation, have been found to be down-regulated also in tumor-surrounding fibroblasts. 91 The reduced posttranscriptional repression of miR-15 and -16 targets, such as FGF-2 and FGFR1, leads to enhanced tumor-supportive capabilities of cancer-associated fibroblasts. When cancer cells were coinoculated with miR-15/16Yreconstituted fibroblasts into the murine background, tumor formation was markedly impaired. Conversely, miR-15/16Ydeficient fibroblasts promoted cancer formation coupled with increased neoangiogenesis. This latter process is crucial in the development of cancer metastasis enabling cancer cells to enter the systemic circulation. The role of miR-15/16 in controlling neoangiogenesis is further corroborated by the targeting of the angiocytokine vascular endothelial growth factor. 92 In conclusion, growing evidence indicates the involvement of miRs in prostate cancer metastases (Figure 1) . If the entity of deregulation of previously mentioned miRs is confirmed in prospective and adequately powered clinical trials, these molecules can be exploited for addressing crucial clinical questions spanning from individualized risk assessment to predicting benefits from bone-acting agents. Furthermore, the mechanistic relationship existing between miR15/16 and angiocytokines makes these miRs worth being investigated to define the patient population responsive to antiangiogenic agents.
MIRS AND ARYMEDIATED SIGNALS
Androgen deprivation therapy is the standard of care for patients who experience distant or biochemical recurrence following radical therapy. Given that the benefit from current hormonal manipulations is transient, it was generally accepted that tumors progressively become independent to androgen stimulation. This paradigm is rapidly changing, and clinical trials with new compounds revealed that prostate cancer still relies on AR signaling, even when disease progression during antihormone therapy is clinically documented. The extended survival emerged with the cytochrome P17 inhibitor abiraterone acetate 5 and the AR antagonist MDV3100 in castration-resistant prostate cancer patients highlights the therapeutic relevance of continued AR signaling targeting. Different mechanisms of AR activation under androgen-depleted conditions have been described: AR gene amplification or mutations, alteration in the AR coactivator/ corepressor balance, and ligand-independent AR activation via ''outlaw'' pathways. 93 This picture is further complicated when considering that also epigenetic changes, such as miR alterations, can sustain AR activity in the hormone-depleted milieu. The oncomirs miR-221 and miR-222 are frequently overexpressed in many cancers, being connected with altered cell cycle kinetics through the modulatory activity on the cell cycle controller p27. Genome-wide expression profiling revealed that these miRs are significantly increased in a panel of castrationresistant prostate cancer cell lines compared with the androgendependent cell line LNCaP. 43 The overexpression of miR-221 or miR-222 in LNCaP cells reduced the dihydrotestosteroneinduced up-regulation of PSA expression (an AR target gene) and led to androgen-independent growth. Conversely, knocking down miR-221 and miR-222 in the androgen-independent cell line impaired their growth rate and restored the reliance on hormonal stimulation. Conversely, miR-let-7c is often downregulated in prostate cancer and expressed at lower levels in castration-resistant cell lines compared with androgen-sensitive cells. Loss of let-7 expression is significantly associated with the presence of poorly differentiated cancers, 94 probably because of its regulatory activity on master oncogenes such as RAS 50 and MYC. 51 The key regulatory activity of this miR is further supported by the inverse relationship existing between let-7c and AR expression. Even more important, the forced overexpression of let-7c led to reduced transcriptional activity of AR, whereas let-7c antisense oligonucleotides determined a marked increase in AR target genes. Interestingly, the let7cYmediated suppression of AR activity is at the transcriptional level, rather than through canonical miR-mediated mRNA degradation. In particular, let-7c suppresses AR expression by targeting the oncogene MYC that, in turn, acts as a transcription factor for the AR. 95 Given the growing number of miRs interfering with the AR pathway, mapping the whole network of miRs associated with continuous AR activation could better define molecular mechanisms underlying the onset of castration-resistant prostate cancer. Therefore, it is of utmost importance to define the panel of miRs able to directly target the AR 3 ¶ UTR, rather than indirectly regulating AR function. Gain-of-function analysis of a miR library, combined with AR protein quantification using reverse-phase protein microarray, revealed that 71 miRs (52 decreasing and 19 increasing) affected AR levels in a panel of tumor cells, with 13 miRs validated in independent 3 ¶ UTRYbinding assays (miR-135b, -185, -297, -299-3p, -34a, -34c, -371Y3p , -421, -449a, -449b, -634, -654-5p, and -9). 96 It is worth considering that the miRs-AR interactions are bidirectional, and AR exerts a regulatory activity on some miRs. Recently, a feedback loop between various miRs, the AR, and its corepressors has been demonstrated. In particular, AR regulates gene expression through 3 different mechanisms including miR activation, corepressor suppression, and DNA interaction. 97 Nevertheless, the exploitation of a nonmalignant model makes it difficult to apply this finding to a malignant context. Genomewide screening of androgen target genes carried out in prostate cancer cells by combining 5 ¶-cap analysis of gene expression and chromatin immunoprecipitation on array (ChIP-chip) analysis successfully identified miR-125b-2, a miR residing on chromosome 21, as androgen-inducible miR. 98 Furthermore, a high-throughput microarray analysis carried out to define ARresponsive miRs revealed miR-21 as one of the top up-regulated miRs when androgen-sensitive cell lines were exposed to the androgen analog R1881. 99 Notably, miR-21 overexpression promoted androgen-independent growth in vitro. These data have been confirmed in vivo by comparing the tumor growth rate of miR-21Ytransduced cells versus control cells upon surgical castration. Whereas castration markedly reduced tumor growth in control tumors, miR-21Ytransduced tumors were unaffected by testosterone suppression. A further microarray analysis identified a set of miRs (miR-21, -32, -99a, -99b, -148a, -221, and -590-5p) differentially expressed in castration-resistant forms compared with benign prostate hyperplasia. 100 The functional study revealed that the overexpressed, androgen-regulated miR-32 targets the oncosuppressor BTG2, whose levels decrease in advanced diseases.
Given the therapeutic relevance of AR signaling during the entire course of the disease, elucidating its interactions with miRs will help to better define molecular mechanisms underlying aberrant AR activation. Overall, whereas miRs regulating the AR could be used for predicting the benefit from hormonal manipulation, AR-modulated miRs can be developed as pharmacodynamic assays for monitoring the target over time during antihormone therapy.
MIRS IN THE CLINICAL SETTING
The expanding complexity of prostate cancer management calls for the need of diagnostic, prognostic, predictive, and pharmacodynamic markers forecasting disease severity and long-term outcomes, driving the therapeutic choice, and monitoring therapy response over time (Figure 2) . The potential contribution of miRs is supported by different observations. First, their multifaceted biological functions could allow mapping deregulated molecular networks by measuring a limited number of molecular endpoints. Second, their high stability in formalin-fixed tissues allows their detection, by in situ hybridization or quantitative polymerase chain reaction (PCR) analysis, in biobanked samples. 101, 102 Third, miRs are present in a markedly stable form in the serum, where their composition seems to contain fingerprints distinctive of given pathological conditions. 103Y106 Therefore, circulating miRs can be particularly useful when tissue samples are unavailable (the adjuvant setting, the biochemical recurrence) or difficult to be collected (skeletal metastases).
A critical hurdle physicians have to face is that borderline PSA levels cannot discriminate between nonneoplastic and neoplastic diseases. In a first report, the comparison of a case-control cohort of serum samples collected from 25 metastatic prostate cancer patients with 25 age-matched controls revealed an increased expression of miR-100, -125b, -141, -143, and -296 in the serum of cancer patients. 107 Next, it has been reported that a panel of 5 miRs, identified in plasma samples through the Illumina's miR expression platform v2 and validated by quantitative real-time PCR, discriminates between BPH and prostate cancer. Authors identified 3 miRs (let-7e, let-7c, and miR-30c) downregulated and 2 miRs (miR-622 and miR-1285) up-regulated in prostate cancer patients, with this finding validated in a larger independent cohort composed of 80 tumors, 44 BPHs, and 54 healthy controls. 108 These results are, however, different from those reported by Moltzahn et al, 109 who, by profiling 48 sera from healthy men and untreated prostate cancer patients with a multiplex quantitative reverse transcription PCR method, identified 4 miRs (miR-223, -26b, -30c, and -24) down-regulated and 6 miRs (miR-20b, -874, -1274a, -1207-5p, -93, and-106a) up-regulated in the prostate cancer group. In addition, miR-93, -106a, and -24 showed variability within different risk categories, particularly the low-and intermediate-risk groups. To a similar extent, expression levels for miR-20a, miR-21, and miR-145 correlated with the Cancer of the Prostate Risk Assessment and D'Amico scores, thus indicating that the integration of these molecular parameters into risk stratification models could improve the accuracy of current predictors. 110 Finally, urinary levels of miR-107 and miR-574-3p have been found to be present at significantly higher concentrations in men with cancer (n = 115) when compared with controls (n = 17). 46 An accurate definition of the subset of patients with high risk of distant recurrence following primary therapy is still challenging. Moreover, the growing availability of active drugs successfully tested for metastatic disease, and that will be evaluated as adjuvant therapy, will require optimal criteria for patient selection. A comparison of miR profiles, obtained with an Exiqon quantitative reverse transcriptaseYPCR microarray panel of 742 miRs and preformed on plasma-derived circulating microvesicles harvested from 16 patients with metastatic and 55 patients with nonmetastatic prostate cancer, revealed a total of 16 differentially represented miRs. Particularly, 15 miRs showed significantly higher concentrations in the metastatic disease (582f-3p, -20a*, -375, -200b, -379, -513a-5p, -577, 23a*, -1236, 609, -17*, -619, -624*, -198, -130b), whereas miR-572 was present at significantly lower levels in the metastatic setting. 46 The evaluation by Taqman quantitative reverse transcriptaseYPCR of 5 miR markers (miR-375, -107, -200b, -141, and -452), with either significant or nonsignificant expression differences in the initial microarray, demonstrated that miR-375 and miR-141 were significantly associated with metastatic disease, a finding confirmed in the analysis of an independent cohort of recurrent (n = 47) or nonrecurrent (n = 72) diseases. Furthermore, a set of 25 miRs (the ''miR predictor''), identified in tissue samples and composed of 13 down-regulated and 12 up-regulated miRs, seemed more accurate in forecasting distant recurrence compared with standard clinical-pathological parameters. 23 However, the robustness of this assay should be further investigated, given the limited number of samples examined in this study, the lack of a validation set, and the comparison to a single prognostic factor rather than composite scores. Next, gene expression profiling carried out in 70 radical prostatectomy specimens, and encompassing a custom panel of 522 prostate cancerYlinked genes, revealed that 10 molecular endpoints, including miR-519d and miR-647, distinguished patients undergoing biochemical recurrence from those recurrence-free. 111 This finding has been validated in an independent analysis on 40 samples. The predictive accuracy of this biomarker panel has been further enforced in an analysis aimed at evaluating the recurrence risk in patients with Gleason score 7, a subset for which risk assessment is particularly difficult. A fourth study evaluated 75 specimens from radically resected patients through miR microarrays for 470 human miRs. 21 High miR-96 expression was associated with significantly decreased recurrence-free interval, with this relationship validated in a second cohort of 79 patients. Furthermore, authors detected 10 down-regulated miRs (miR-16, -31, -125b, -145, -149, -181b, -184, -205, -221, and -222) and 5 up-regulated miRs (miR-96, -182, -182*, -183, and -375) in malignant versus normal adjacent tissues.
MicroRNAs have also been proposed as predictive biomarkers. The identification and validation of response predictors are of utmost importance in clinical practice, allowing FIGURE 2. MicroRNAs can be exploited as biomarkers for improving the accuracy of PSA-based screening test, for increasing the accuracy of current recurrence predictors, and for predicting the benefit from hormone therapy and chemotherapy.
maximizing the therapeutic potential of anticancer agents while sparing patients from unnecessary adverse effects. The evaluation of 61 single nucleotide polymorphisms inside miRs and miR target sites in a cohort of 601 Chinese Han men with advanced prostate cancer receiving androgen deprivation therapy revealed that 3 different sets of single nucleotide polymorphisms are associated with disease progression, prostate cancer-specific mortality, and all-cause mortality. 112 Therefore, it has been suggested that miR-based genotyping could be used for predicting the benefit from hormonal therapies. Once patients fail androgen deprivation therapy, they are candidate to docetaxel-containing chemotherapy. Higher levels of serum miR-21 before chemotherapy have been associated with ineffectiveness of chemotherapy (4/10 patients), whereas the 6 patients who experienced a PSA response presented with lower miR-21 levels. 113 Finally, miR-141 has been investigated to monitor treatment response in 21 metastatic prostate cancer patients. 114 Changes in miR-141 level predicted the clinical outcome and coincided with the fluctuations of other established biomarkers such as PSA, circulating tumor cells, and lactate dehydrogenase. Therefore, miRs hold promise as easily detectable biomarkers, albeit clinical studies are biased by multiple factors. How racial factors, the size and retrospective nature of aforementioned studies, the heterogeneity of technological platforms exploited, the type of biological samples examined (tissues, sera, urine), and the matching strategy (health individuals or paired normal adjacent tissue from the same prostate) account for such discrepancies are nodes that have to be solved before embarking in large prospective trials.
CONCLUSIONS
If, on the one hand, the discovery of miRs has added a further layer of complexity to the pathobiology of neoplastic diseases, on the other hand their multifaceted functions make them an attractive candidate for developing innovative diagnostic tests and prognostic/predictive biomarkers. Their tight correlation with key features of cancer provides a ready background for biology-driven investigations in the clinical setting. However, the inconsistency of data has to be overcome before diagnostic, prognostic, and predictive miRs can be translated to the bedside. To this end, adequately powered, well-designed clinical trials are needed for sharpening the potential of miRs in the whole spectrum of their applications. Finally, the exploitation of these small molecules as candidate therapeutics could offer the possibility of interfering with multiple deregulated pathway nodes/biological functions in a ''one-shot'' strategy.
